icon-folder.gif   Conference Reports for NATAP  
  EASL 45th Annual Meeting
April 14-18, 2010
Vienna, Austria
Back grey_arrow_rt.gif
Ritonavir boosting of low-dose danoprevir (RG7227; ITMN-191), HCV NS3/4A protease inhibitor, results in robust reduction in HCV RNA at lower exposures than provided by unboosted regimens
  Reported by Jules Levin
EASL Apr 14-18 2010
Vienna Austria
Auckland Clinical Studies, Auckland, New Zealand; CENTRE CAP, France; Christchurch Clinical Studies Trust, Christchurch, New Zealand; Department of Hepatology and Immunodeficiencies, Warsaw Medical University, Poland; Warsaw Medical University & Hospital of Infectious Diseases, Warsaw, Poland; Roche, USA

CYP3A = cytochrome P450 3A

"Figure description: An unboosted high dose of a rapidly cleared compound requires a high AUC and a Cmax to achieve an acceptable trough concentration. With RTV boosting, it is possible for a much lower dose to provide a superior trough concentration, even while overall exposure and Cmax are reduced"